NCT01520116Unknown1 期
A Phase 1/2a Randomized, Investigator-masked, Placebo- and Active-controlled, Dose-ranging Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 180
- 主要终点
- Mean Change in Intraocular Pressure from Baseline
研究概览
简要总结
This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or latanoprost in subjects with primary open angle glaucoma or ocular hypertension. In the first portion, approximately 75 subjects will be randomized to receive either ATS907 or vehicle eye drops for up to 28 days, administered both once and twice daily. In the second portion, up to 180 subjects will be randomized to receive either ATS907 or latanoprost for up to 28 days. Plasma pharmacokinetics will also be evaluated during the first portion of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or greater
- •Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes
- •Unmedicated (post-washout) IOP ≥ 23 mm Hg at 2 eligibility visits: 07:00-09:00 hr on Days O and 1 and IOP > 18 mm Hg at 15:00-17:00 on Day 0 (Stage 1)
- •Unmedicated (post-washout) IOP criteria after wash out < 32 mm Hg OU at all times points (Stage 1)
- •Unmedicated (post-washout) IOP ≥ 24 mm Hg at 2 eligibility visits: 07:00-09:00 hr on Days O and 1 and IOP > 21 mm Hg at 9:00-17:00 on Day 0 (Stage 2)
- •Unmedicated (post-washout) IOP criteria after wash out < 36 mm Hg OU at all times points (Stage 2)
- •Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200)
- •Must be willing to discontinue the use of all ocular hypotensive medications in both eyes prior to and during the entire course of the study
排除标准
- •Ophthalmic (in either eye)
- •Glaucoma: pseudoexfoliation, steroid induced, pigment dispersion glaucoma, and or history of angle closure. Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s). Prior laser glaucoma surgery is permitted in the non study eye
- •Refractive surgery in study eye (e.g., radial keratotomy, PRK, LASIK, etc.)
- •Cataract surgery and or other intraocular surgery within three months prior to Screening in either eye.
- •History within 3 months prior to Screening of clinically significant moderate or severe chronic or active ocular infection, inflammation, blepharitis, dermatitis, uveitis or conjunctivitis.
- •Clinically significant corneal dystrophy, epithelial and or endothelial disease, corneal irregularities and or scarring such that reliable applanation tonometry would prevented.
- •Contact lens wear during the duration of the study.
- •Clinically significant ocular disease (e.g. diabetic retinopathy, macular degeneration, or uveitis) which might interfere or progress during the study.
- •Central corneal thickness < 480 or > 600 μm in the study eye
- •Clinically significant abnormalities in laboratory tests at screening.
- •Clinically significant systemic disease (e.g., uncontrolled diabetes, uncontrolled hyper or hypotension, hepatic, renal, endocrine or cardiovascular disorders). Participation in any investigational study within the past 30 days.
- •Changes of systemic medication that could have a substantial effect on IOP and or systemic blood pressure within 7 days prior to Baseline (Day 0).
- •Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the Screening visit and a negative urine and serum pregnancy at Baseline (Day 0) and must not intend to become pregnant during the study
研究组 & 干预措施
Stage 1 - Arm 1 - Dose 1
Experimental
干预措施: Stage 1 - ATS907 - Dose 1 (Drug)
Stage 1 - Arm 2 - Dose 2
Experimental
干预措施: Stage 1 - ATS907 - Dose 2 (Drug)
Stage 1 - Arm 3 - Dose 3
Experimental
干预措施: Stage 1 - ATS907 - Dose 3 (Drug)
Stage 1 - Arm 4 - Dose 4
Experimental
干预措施: Stage 1 - ATS907 - Dose 4 (Drug)
Stage 1 - Arm 5 - Vehicle
Placebo Comparator
干预措施: Stage 1 - Vehicle (Drug)
Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1
Experimental
干预措施: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1 (Drug)
Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1
Experimental
干预措施: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1 (Drug)
Stage 2 - Arm 3 -Timoptic 0.5% BID
Active Comparator
干预措施: Timoptic (Drug)
结局指标
主要结局
Mean Change in Intraocular Pressure from Baseline
时间窗: Stage 1: Days 14, 21 and 28; Stage 2: Day 4
次要结局
- Observed Intraocular Pressure and % change from Baseline IOP(Stage 1: Days 0, 1, 4, 14, 21, 28; Stage 2: Days 0, 4)
- Mean observed, mean change from Baseline and mean % change from Baseline for the mean diurnal IOP(Stage 1: Days 0, 1, 4, 14, 21, 28; Stage 2: Days 0, 4)
研究者
相似试验
终止
1 期
Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and ImmunogenicityClostridium Difficile InfectionClostridium Difficile DiarrheaNCT00772954Sanofi36
终止
1 期
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)AMNAMN Gene MutationX-ALDNCT05394064SwanBio Therapeutics, Inc.9
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative ColitisUlcerative ColitisNCT04862741Landos Biopharma Inc.39
招募中
1 期
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.Pneumococcal InfectionsNCT05667740GPN Vaccines117
招募中
2 期
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Carcinoma, HepatocellularNCT06349980Shanghai Henlius Biotech117